Europe Spells Out Conditions For Return Of Ranitidine
Executive Summary
EMA has set out four conditions which marketing authorization holders must meet before the suspension of ranitidine across Europe can be lifted.
You may also be interested in...
EU Nitrosamines Oversight Group Sets Priorities
After agreeing on an EU-wide harmonized approach to deal with nitrosamine contamination in medicines, a recently formed regulatory oversight group has identified several topics requiring further scientific discussion.
After Finding Nitrosamine In Ranitidine, US Firm Suggests Link To Higher Cancer Diagnosis Rates
JAMA study found under simulated gastric conditions a standard tablet of ranitidine yielded NDMA to three orders of magnitude beyond established exposure limits. Rapid formation of NDMA appears to continue for extended periods in gastric conditions, say researchers from Memorial Sloan Kettering and Valisure.
EMA Stands By Suspension Of Ranitidine In EU After Re-Examination
Suspension of heartburn remedy ranitidine looming in the EU as the European Medicines Agency stands by its original decision.